DARE | tickerfilter.com

Fundamental analysis

22%

Profitability 0%

Dept financing 50%

Liquidity 47%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-1.54%

1 Month

-2.20%

3 Months

-11.23%

6 Months

-11.50%

1 Year

477.81%

2 Year

-75.47%

Key data

Stock price

$2.88

P/E Ratio

0.00

DAY RANGE

$2.88 - $2.89

EPS

$0.73

52 WEEK RANGE

$0.28 - $5.64

52 WEEK CHANGE

$512.53

MARKET CAP

27.690 M

YIELD

N/A

SHARES OUTSTANDING

8.546 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-13-2025

BETA

2.17

PUBLIC FLOAT

AVERAGE 10 VOLUME

$20,876

AVERAGE 30 VOLUME

$18,980

Company detail

CEO: Sabrina M. Johnson
Region: US
Website: darebioscience.com
Employees: 30
IPO year: 2014

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Daré Bioscience, Inc. develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive.

DARE - Dare Bioscience, Inc.